» Articles » PMID: 22644142

A Multidisciplinary Clinic for Individualizing Management of Patients at Increased Risk for Breast and Gynecologic Cancer

Overview
Journal Fam Cancer
Publisher Springer
Specialty Oncology
Date 2012 May 31
PMID 22644142
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing awareness of the hereditary component of breast and ovarian cancer has driven interest in creating clinics for the patient population at high risk for these cancers. Identifying adequate space and appropriate staff, coordinating multiple providers' schedules, establishing referral criteria, and addressing billing and reimbursement concerns are just some of the issues that are involved in the creation of a multidisciplinary high risk breast and ovarian cancer program. We provide an overview of the clinic structure at the Magee-Womens Hospital High Risk Breast and Ovarian Cancer Program (HRBOCP), which was created in 2002 due to recognition of a need for a more coordinated model of providing care for women at increased risk for breast and ovarian cancer. The goals of the HRBOCP are to evaluate women at high risk for breast and ovarian cancer and to organize their clinical care in a multidisciplinary setting staffed by experts in the field; to provide updates on new data regarding screening recommendations, prevention options, and risk factors pertinent to an individual's cancer risk; to provide ongoing support to patients and to coordinate family communication when appropriate; and to facilitate enrollment in appropriate research studies and registries.

Citing Articles

A cost-benefit analysis of genetic screening test for breast cancer in Iran.

Meshkani Z, Moradi N, Aboutorabi A, Farabi H, Moini N BMC Cancer. 2024; 24(1):279.

PMID: 38429685 PMC: 10905849. DOI: 10.1186/s12885-024-12003-4.


Real World Cost-Effectiveness Analysis of Population Screening for BRCA Variants among Ashkenazi Jews Compared with Family History-Based Strategies.

Michaelson-Cohen R, Cohen M, Cohen C, Greenberg D, Shmueli A, Lieberman S Cancers (Basel). 2022; 14(24).

PMID: 36551598 PMC: 9776581. DOI: 10.3390/cancers14246113.


Hereditary ovarian cancer risk reduction: a retrospective evaluation of patient perspectives and service provision at a regional hereditary gynaecologic cancer clinic 2006-2016.

Adolph L, Warias A, Stairs J, Collins-McNeil K, Penney L, Kieser K BMC Womens Health. 2022; 22(1):263.

PMID: 35768821 PMC: 9245201. DOI: 10.1186/s12905-022-01844-5.


Population or family history based BRCA gene tests of breast cancer? A systematic review of economic evaluations.

Meshkani Z, Aboutorabi A, Moradi N, Langarizadeh M, Ghanbari Motlagh A Hered Cancer Clin Pract. 2021; 19(1):35.

PMID: 34454549 PMC: 8399845. DOI: 10.1186/s13053-021-00191-0.


Involvement and Influence of Healthcare Providers, Family Members, and Other Mutation Carriers in the Cancer Risk Management Decision-Making Process of BRCA1 and BRCA2 Mutation Carriers.

Puski A, Hovick S, Senter L, Toland A J Genet Couns. 2018; 27(5):1291-1301.

PMID: 29594659 PMC: 6612901. DOI: 10.1007/s10897-018-0254-4.


References
1.
Sabatino S, McCarthy E, Phillips R, Burns R . Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev. 2007; 31(5):375-83. DOI: 10.1016/j.cdp.2007.08.003. View

2.
Walsh T, Casadei S, Coats K, Swisher E, Stray S, Higgins J . Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA. 2006; 295(12):1379-88. DOI: 10.1001/jama.295.12.1379. View

3.
Cusack Jr J, Hughes K . Managing patients at high risk for hereditary breast cancer: a guide for the practicing physician. Ann Surg Oncol. 2012; 19(6):1721-2. DOI: 10.1245/s10434-012-2255-0. View

4.
Casadei S, Norquist B, Walsh T, Stray S, Mandell J, Lee M . Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011; 71(6):2222-9. PMC: 3059378. DOI: 10.1158/0008-5472.CAN-10-3958. View

5.
Hilgart J, Coles B, Iredale R . Cancer genetic risk assessment for individuals at risk of familial breast cancer. Cochrane Database Syst Rev. 2012; (2):CD003721. PMC: 7154385. DOI: 10.1002/14651858.CD003721.pub3. View